Innovent Biologics (Suzhou) Co. Ltd.

Quick facts

Marketed products

• Intensive treatment
  Inhibits programmed death-ligand 1 (PD-L1) to restore T-cell mediated immune response against cancer cells.
• regular treatment
  Unable to determine specific mechanism without additional drug identifier or name.
• Teprotumumab N01 · Immunology / Ophthalmology
  Teprotumumab is a human monoclonal antibody that inhibits insulin-like growth factor-1 receptor (IGF-1R) signaling to reduce inflammation and fibrosis in thyroid eye disease.

Phase 3 pipeline

• dose 1 IBI302 · Oncology
  IBI302 is an anti-PD-1 monoclonal antibody that works by binding to the PD-1 receptor and blocking its interaction with PD-L1, thereby enhancing T-cell mediated immune response.
• IBI301 plus CHOP · Oncology
  IBI301 is a PD-L1 inhibitor combined with CHOP chemotherapy to enhance anti-tumor immune response while providing cytotoxic chemotherapy.
• IBI303 · Oncology
  IBI303 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.
• IBI305 · Oncology
  IBI305 is a PD-L1 inhibitor that blocks the interaction between PD-L1 on tumor cells and PD-1/B7.1 on immune cells, thereby restoring anti-tumor immune responses.
• IBI306 · Oncology
  IBI306 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.
• IBI308 · Oncology
  IBI308 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.
• IBI310 · Oncology
  IBI310 is a bispecific antibody that simultaneously engages PD-1 on T cells and TIM-3 on tumor-infiltrating lymphocytes to enhance anti-tumor immune responses.
• IBI310&Sintilimab · Oncology
  IBI310 is a bispecific antibody that simultaneously blocks CTLA-4 and TIM-3 checkpoints to enhance anti-tumor immunity, while Sintilimab is a PD-1 inhibitor that releases PD-1-mediated immune suppression.
• IBI343 · Oncology
  IBI343 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity.
• IBI354 · Oncology
  IBI354 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity.
• IBI362 · Oncology
  IBI362 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity.
• IBI363 · Oncology
  IBI363 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TIM-3 on T cells to enhance anti-tumor immune responses.
• paclitaxel/Gemcitabine/Liposomal doxorubicin · Oncology
  Paclitaxel inhibits microtubule dynamics, Gemcitabine is a nucleoside analog that inhibits DNA synthesis, and Liposomal doxorubicin is an anthracycline antibiotic that intercalates DNA.
• placebo /IBI112 · Oncology
  IBI112 is an anti-PD-1 monoclonal antibody.
• Placebo SC Q4W
  This is a placebo control used in clinical trials and does not exert any active pharmacological effect.
• Placebo2
  Placebo2 does not have an active pharmacological mechanism; it is designed as a control in clinical trials.

Phase 2 pipeline

• IBI128
• IBI3016
• IBI318
• IBI343,Gemcitabine, Albumin-bound Paclitaxel · Oncology
  Gemcitabine is a nucleoside analog that inhibits DNA synthesis by interfering with DNA polymerase.
• IBI343,sintilimab,oxaliplatin,S-1 · Oncology
  Programmed death-ligand 1 inhibitor
• IBI356
• Period 2 IBI112 dose 3
• sintilimab,oxaliplatin,S-1

Phase 1 pipeline

• [14C] IBI351
• bevacizumab with new manufacturing process.
• bevacizumab with old manufacturing process.
• Biological: IBI322
• dose-1 group
• dose-2 group
• dose-3 group
• dose-4 group
• dose-5 group
• Dupilumab for MAD
• IBI 360 Injection Sintilimab
• IBI101
• IBI110
• IBI110 plus sintilimab
• IBI129
• IBI130
• IBI133
• IBI3001
• IBI3005
• IBI3009
• IBI301
• IBI3011
• IBI3014
• IBI3033
• IBI308 200mg
• IBI308\cisplatin\gemcitabine
• IBI308\Cisplatinum\Pemetrexed
• IBI308\etoposide\cisplatin
• IBI308\irinotecan\5-FU
• IBI308\oxaliplatin\capecitabine
• IBI315
• IBI319
• IBI321
• IBI323
• IBI324
• IBI325
• IBI333
• IBI334
• IBI345
• IBI351

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Innovent Biologics (Suzhou) Co. Ltd. portfolio CI brief
• Innovent Biologics (Suzhou) Co. Ltd. pipeline updates RSS